Brigatinib BDBM50185140 AP-26113 US11248003, Example Brigatinib US20230322822, Compound Brigatinib
- Li, S; Zhang, T; Zhu, SJ; Lei, C; Lai, M; Peng, L; Tong, L; Pang, Z; Lu, X; Ding, J; Ren, X; Yun, CH; Xie, H; Ding, K Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR ACS Med Chem Lett 13: 196-202 (2022)
- Sun, N; Ren, C; Kong, Y; Zhong, H; Chen, J; Li, Y; Zhang, J; Zhou, Y; Qiu, X; Lin, H; Song, X; Yang, X; Jiang, B Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. Eur J Med Chem 193: (2020)
- Ren, C; Sun, N; Liu, H; Kong, Y; Sun, R; Qiu, X; Chen, J; Li, Y; Zhang, J; Zhou, Y; Zhong, H; Yin, Q; Song, X; Yang, X; Jiang, B Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile. J Med Chem 64: 9152-9165 (2021)
- Fang, H; Wu, Y; Xiao, Q; He, D; Zhou, T; Liu, W; Yang, CH; Xie, Y Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR Bioorg Med Chem Lett 72: (2022)
- Huang, WS; Liu, S; Zou, D; Thomas, M; Wang, Y; Zhou, T; Romero, J; Kohlmann, A; Li, F; Qi, J; Cai, L; Dwight, TA; Xu, Y; Xu, R; Dodd, R; Toms, A; Parillon, L; Lu, X; Anjum, R; Zhang, S; Wang, F; Keats, J; Wardwell, SD; Ning, Y; Xu, Q; Moran, LE; Mohemmad, QK; Jang, HG; Clackson, T; Narasimhan, NI; Rivera, VM; Zhu, X; Dalgarno, D; Shakespeare, WC Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. J Med Chem 59: 4948-64 (2016)